Article
A Practical Review of Encorafenib and Binimetinib Therapy Management in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer.
Advances in therapy - 1 Jul 2024
Baik Christina, Cheng Michael L, Dietrich Martin, Gray Jhanelle E, Karim Nagla A
Abstract excerpt
According to current guidelines, targeted therapy with a combination of BRAF plus MEK inhibitors is the preferred first-line treatment for patients with BRAF V600E-mutant metastatic non-small cell lung cancer (NSCLC). In the open-label, single-arm, phase 2 PHAROS trial (NCT03915951), the combination of encorafenib, a potent BRAF inhibitor, and binimetinib, a potent MEK inhibitor, demonstrated durable antitumor...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.